PRAD-Hybrid CNN (PRADHC): A Deep Learning Model for Assisted Diagnosis of Prostate Cancer on MRI.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
64 patients.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
However, it is imperative to acknowledge that false-positive lesion detections remain a limitation of AI-assisted diagnostic tools. Nevertheless, this system can serve as a valuable supplementary instrument for radiologists in their diagnostic endeavors.
[BACKGROUND] Prostate cancer is a prevalent malignancy in males, with prostate MRI imaging as the primary diagnostic method.
APA
Liu J, Hou L, et al. (2026). PRAD-Hybrid CNN (PRADHC): A Deep Learning Model for Assisted Diagnosis of Prostate Cancer on MRI.. Current medical imaging. https://doi.org/10.2174/0115734056413897251202130301
MLA
Liu J, et al.. "PRAD-Hybrid CNN (PRADHC): A Deep Learning Model for Assisted Diagnosis of Prostate Cancer on MRI.." Current medical imaging, 2026.
PMID
41837512
Abstract
[BACKGROUND] Prostate cancer is a prevalent malignancy in males, with prostate MRI imaging as the primary diagnostic method. However, this method is subjective and can miss early-stage cancers, necessitating more efficient diagnostic techniques.
[METHOD] In this study, we introduced the PRAD-Hybrid CNN (Prostate Adenocarcinoma Hybrid Convolutional Neural Network, PRADHC) model, a novel amalgamation of EfficientNet and Residual Blocks, which was developed and validated on 1,528 MRI images from 64 patients. By strategically increasing the number of Convolutional Neural Network (CNN) layers in the EfficientNet architecture, our model improved the diagnostic accuracy inherent to the original EfficientNet. Additionally, the integration of Residual Networks (ResNet) successfully mitigated the gradient vanishing issue often encountered during the training of deeper models, thereby significantly enhancing training accuracy. This innovative model, thus, offers clinicians an efficacious tool for assisted diagnosis.
[RESULT] The PRADHC model, upon validation, achieved an accuracy of 99.34% and an AUC of 99.32%, a 4% improvement over the conventional EfficientNet. The baseline elementary CNN model achieved 95.72% accuracy and 96.74% AUC, which is still lower than the PRADHC model.
[CONCLUSION] This study introduces a novel deep learning model designed specifically for the automated diagnosis of prostate cancer. This model aims to enhance diagnostic accuracy, especially in the early stages of the disease. Such advancements have the potential to augment the diagnostic proficiency of both radiologists and urologists, assisting them in more informed decision-making regarding treatment planning. However, it is imperative to acknowledge that false-positive lesion detections remain a limitation of AI-assisted diagnostic tools. Nevertheless, this system can serve as a valuable supplementary instrument for radiologists in their diagnostic endeavors.
[METHOD] In this study, we introduced the PRAD-Hybrid CNN (Prostate Adenocarcinoma Hybrid Convolutional Neural Network, PRADHC) model, a novel amalgamation of EfficientNet and Residual Blocks, which was developed and validated on 1,528 MRI images from 64 patients. By strategically increasing the number of Convolutional Neural Network (CNN) layers in the EfficientNet architecture, our model improved the diagnostic accuracy inherent to the original EfficientNet. Additionally, the integration of Residual Networks (ResNet) successfully mitigated the gradient vanishing issue often encountered during the training of deeper models, thereby significantly enhancing training accuracy. This innovative model, thus, offers clinicians an efficacious tool for assisted diagnosis.
[RESULT] The PRADHC model, upon validation, achieved an accuracy of 99.34% and an AUC of 99.32%, a 4% improvement over the conventional EfficientNet. The baseline elementary CNN model achieved 95.72% accuracy and 96.74% AUC, which is still lower than the PRADHC model.
[CONCLUSION] This study introduces a novel deep learning model designed specifically for the automated diagnosis of prostate cancer. This model aims to enhance diagnostic accuracy, especially in the early stages of the disease. Such advancements have the potential to augment the diagnostic proficiency of both radiologists and urologists, assisting them in more informed decision-making regarding treatment planning. However, it is imperative to acknowledge that false-positive lesion detections remain a limitation of AI-assisted diagnostic tools. Nevertheless, this system can serve as a valuable supplementary instrument for radiologists in their diagnostic endeavors.
같은 제1저자의 인용 많은 논문 (5)
- A graded approach in East Asian personalized lower blepharoplasty: A retrospective study spanning 12 years.
- Review of complications in double eyelid surgery.
- Spatial transcriptomics and single-cell analyses reveal the role of the cisplatin-resistant gene panel in NSCLC progression and the tumor microenvironment, identifying LOXL2 as a potential therapeutic target.
- Association between C-reactive protein-to-albumin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study.
- CX3CL1/CX3CR1 axis in liver disease: context-dependent roles and balance.